Standout Papers
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (2018)
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) (2013)
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial (2020)
Immediate Impact
7 by Nobel laureates 25 from Science/Nature 105 standout
Citing Papers
Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
2024 Standout
Works of Roberto Hegg being referenced
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Roberto Hegg | 6369 | 2253 | 2291 | 80 | 8.0k | |
| David Miles | 5878 | 2119 | 1303 | 92 | 8.2k | |
| Roberto Salgado | 6284 | 1650 | 2512 | 146 | 8.4k | |
| Lukas C. Amler | 4785 | 2803 | 2628 | 97 | 9.4k | |
| Jane Yuet Ching Hui | 4787 | 1776 | 1694 | 98 | 6.4k | |
| Eva Ciruelos | 5094 | 2263 | 2371 | 206 | 6.8k | |
| Peter Schmid | 8002 | 3424 | 3134 | 203 | 10.6k | |
| Priti Lal | 2958 | 2376 | 1961 | 124 | 6.6k | |
| Tadeusz Pieńkowski | 9343 | 2438 | 3720 | 129 | 11.6k | |
| Graham Ross | 7823 | 2140 | 2161 | 42 | 9.0k | |
| Janet Wolter | 9010 | 2290 | 2869 | 30 | 12.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...